Drugs / TO-O-1007
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07668804 | Jun 2026 → Aug 2027 expected | dry age related macular degeneration | Theratocular Biotek Co. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TO-O-1007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07668804 ↗ |
| Action | Inhibit | “continuously inhibiting C3/C5 activation” NCT07668804 ↗ |
| Route | Intravitreal | “administered by intravitreal injection” NCT07668804 ↗ |